GSK plc

GSK plc EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GSK plc (GSK.L) as of Oct 16, 2026 is 7.89 B GBP. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 5.72 B GBP — a change of 37.97% (higher).

EBITDA

7.89 BGBP

YoY

37.97%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GSK plc is 2025 7.89 B GBP. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GSK plc was 2024 5.72 B GBP. It decreases by 37.97% higher compared to the previous year.

The GSK plc EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
8.04 B GBP
Jan 1, 2019
7.85 B GBP
Jan 1, 2020
8.26 B GBP
Jan 1, 2021
5.51 B GBP
Jan 1, 2022
6.77 B GBP
Jan 1, 2023
7.07 B GBP
Jan 1, 2024
5.72 B GBP
Jan 1, 2025
7.89 B GBP
The GSK plc EBITDA history
YEAREBITDAYoY
7.89 BGBP+37.97%
5.72 BGBP-19.08%
7.07 BGBP+4.31%
6.77 BGBP+23.01%
5.51 BGBP-33.33%
8.26 BGBP+5.24%
7.85 BGBP-2.44%
8.04 BGBP+0.30%
8.02 BGBP+16.71%
6.87 BGBP+52.62%
4.50 BGBP-9.43%
4.97 BGBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GSK plc Stock analysis

What does GSK plc do? GSK plc, listed on the London Stock Exchange under the ticker GSK.L, is a pharmaceutical company headquartered in Brentford, United Kingdom. The company, which has been publicly traded since May 22, 1972, operates within the healthcare sector, specifically in the pharmaceuticals industry. GSK employs 94,066 full-time staff, focusing on the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. The company's operations are structured around two primary segments: Pharmaceuticals and Vaccines. In the Pharmaceuticals segment, GSK develops and markets medicines for a variety of conditions, including respiratory diseases, HIV and infectious diseases, immuno-inflammation, oncology, and rare diseases. The Vaccines segment provides immunization solutions for all age groups, from infants to the elderly, including pediatric, adolescent, adult, and travel vaccines. GSK's portfolio includes prescription medicines and vaccines, with a particular emphasis on respiratory and HIV-related treatments. The company's business strategy encompasses both innovative therapeutic areas and established product lines, supporting its global presence in healthcare. GSK's official website is www.gsk.com, offering further information about its products and initiatives. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GSK plc is 7.89 B GBP in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of GSK plc changed from 5.72 B GBP to 7.89 B GBP, representing a 37.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) GSK plc since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — GSK plc

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — GSK plc